Strides Shasun receives US FDA approval for Parkinson's disease treatment

Insight Weekly: US inflation soars; real estate faces slowdown; megadeals drive tech M&A

Commercial Banking: June 22nd Edition

Understanding Loss Given Default A Review of Three Approaches

Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy

Strides Shasun Ltd. said the U.S. Food and Drug Administration approved its amantadine hydrochloride capsules USP, 100 milligrams.

The drug, which the company will launch immediately, is used as treatment for Parkinson's disease and as pain reliever in the treatment of shingles.

The U.S. market for the product is about $25 million with three generic players, Strides Shasun said in a news release, citing IMS data.